Novistig (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide blocks muscarinic acetylcholine receptors, which diminishes parasympathetic activity and reduces glandular secretions, helping to keep the airway clear while the patient recovers from anaesthesia.

The specific dose of Novistig is determined by the prescribing clinician based on the patient’s weight, the type of muscle relaxant used, and the clinical situation. No fixed regimen is provided in public literature.

Safety data for Novistig in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

Enquiries are submitted via the product page on gnhindia.com where you specify the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Novistig combines an anticholinergic with an acetylcholinesterase inhibitor, offering both secretion control and neuromuscular reversal in a single formulation. Alternative agents may provide only one of these actions, requiring separate drugs and additional monitoring.

Novistig should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Follow the manufacturer’s packaging instructions to maintain product stability.

Novistig is given intravenously by a qualified healthcare professional. The solution is typically administered as a slow IV push or infusion, with continuous monitoring of cardiac rhythm, blood pressure and neuromuscular function.

Serious risks include bronchospasm, severe bradyarrhythmia and anaphylactic reactions. Prompt recognition and immediate management of these events are essential during and after administration.

Patients with known hypersensitivity to glycopyrronium, neostigmine, or any component of the formulation, as well as those with uncontrolled asthma, severe bradycardia, or certain cardiac conduction disorders, should avoid Novistig unless a specialist determines that benefits outweigh risks.